Wednesday’s dominant story is Virginia Governor Abigail Spanberger’s decision to veto legislation that would have created the state’s first licensed cannabis retail market, leaving personal possession legal and the unregulated market unaddressed for at least another year. Fresh federal guidance confirms that rescheduling has not changed drug-testing rules for six million safety-sensitive transport workers, a University of Pennsylvania study adds to evidence that medical cannabis can reduce opioid dependence, and two senior US cannabis lawyers offer a sober assessment of what Schedule III does — and does not — deliver for the industry.
The Department of Transportation issued guidance on 19 May making clear that the rescheduling of state-licensed medical cannabis to Schedule III does not alter federal drug-testing rules for safety-sensitive workers. Truck drivers, pilots, train operators and others in those roles remain prohibited from cannabis use, with the agency stating that “marijuana use is not compatible with safety-sensitive functions.” Marijuana Moment notes the policy covers approximately six million workers. House Transportation Committee chairs have separately introduced bipartisan legislation requiring federal agencies to develop “evidence-based impairment standards” for cannabis across transport modes, though no committee vote is yet scheduled. Further background is available on the Cannabis Rescheduling hub.
Governor Spanberger vetoed legislation that would have launched Virginia’s licensed adult-use cannabis retail market on 1 January 2027, after the General Assembly rejected her proposed amendments at a reconvened session. Spanberger sought to delay the launch to July 2027, raise the excise tax from 6 to 8 per cent, and reduce per-transaction purchase limits; lawmakers declined to adopt the full package, returning the original bill to her desk. Marijuana Moment quotes Senator Lashrecse Aird saying the decision “leaves the commonwealth exactly where we have been since 2021: with an unchecked illicit market.” Personal possession and home cultivation have been legal in Virginia since 2021, but no licensed retail framework has been established. This is the second gubernatorial veto of a cannabis sales bill in the state’s recent legislative history.
A prospective observational study from the University of Pennsylvania, published in the journal Cureus, found that medical cannabis reduced mean daily opioid consumption by 65 per cent among chronic pain patients over a five-month follow-up. The 29 participants, drawn from a university outpatient pain clinic, cut opioid use from 46.8 morphine milligram equivalents per day at baseline to 16.2 MMEs per day within the first month, with seven patients stopping opioid therapy entirely. Pain scores and physical functioning both improved throughout the study period. Researchers describe it as the first prospective study to evaluate medical cannabis as an opioid alternative in a setting where patient cost was not a barrier. The paper carries acknowledged caveats around the small sample and single-site design. The Marijuana Herald reported the findings.
Speaking ahead of Cannabis Europa London (26–27 May), Jonathan Havens and Adam Fayne, partners at law firm Saul Ewing, argue that the DEA’s April rescheduling is historic but frequently misread. In an interview with Business of Cannabis, Havens describes the move as “the most consequential federal change to cannabis law in more than 50 years,” pointing to the elimination of the Section 280E tax disallowance — which had pushed effective federal rates above 70 per cent for some operators — and the creation of new DEA registration and import-export permitting pathways. The pair stress, however, that Schedule III “is not federal legalisation”: adult-use operations remain unaddressed pending the 29 June administrative hearing, banking reform is unresolved, and the legal architecture spanning import-export permits, divergent hemp definitions, and FDA-EMA alignment requires specialist expertise to navigate. GMP-compliant European producers are identified as among the clearest near-term beneficiaries of the new cross-border permitting framework.
Barry Laxer, founder and president of Canadian cannabis producer Cielo Verde, says the European medical cannabis market is shifting “from early supply-driven dynamics toward a more sophisticated ecosystem where quality, reliability, and long-term partnerships matter.” Speaking to Business of Cannabis for its Voices of Cannabis Europa series, Laxer cautions operators against competing on volume, arguing that sustainable businesses must create “value beyond price alone” through strong brand positioning, distinct terpene profiles, and consistent product performance. He identifies the premium segment as underserved and points to research collaborations with McGill’s cannabis research centre and Quebec’s quality control chemists as differentiators for Cielo Verde’s European positioning. The company sponsors the Clinic of the Year award at Cannabis Europa, reflecting its focus on patient-centred care and physician education. See further analysis on the EU Cannabis Regulation hub.
Watch this week for any signal on whether Virginia’s General Assembly will attempt a veto override, and for developments from the Cannabis Europa London conference beginning 26 May. The DEA’s administrative hearing on broader cannabis rescheduling is set for 29 June; 20 May marks the postal deadline for written notices of intent to participate.
The post Cannabis News Today — Wednesday 20 May 2026: Virginia Governor Kills Sales Bill as DOT Holds Line on Transport Drug Testing appeared first on Business of Cannabis.
Continue reading...
Federal Drug Testing Rules Hold for Transport Workers After Rescheduling
The Department of Transportation issued guidance on 19 May making clear that the rescheduling of state-licensed medical cannabis to Schedule III does not alter federal drug-testing rules for safety-sensitive workers. Truck drivers, pilots, train operators and others in those roles remain prohibited from cannabis use, with the agency stating that “marijuana use is not compatible with safety-sensitive functions.” Marijuana Moment notes the policy covers approximately six million workers. House Transportation Committee chairs have separately introduced bipartisan legislation requiring federal agencies to develop “evidence-based impairment standards” for cannabis across transport modes, though no committee vote is yet scheduled. Further background is available on the Cannabis Rescheduling hub.
Virginia Governor Vetoes Cannabis Sales Bill, Leaving State Without Licensed Retail Market
Governor Spanberger vetoed legislation that would have launched Virginia’s licensed adult-use cannabis retail market on 1 January 2027, after the General Assembly rejected her proposed amendments at a reconvened session. Spanberger sought to delay the launch to July 2027, raise the excise tax from 6 to 8 per cent, and reduce per-transaction purchase limits; lawmakers declined to adopt the full package, returning the original bill to her desk. Marijuana Moment quotes Senator Lashrecse Aird saying the decision “leaves the commonwealth exactly where we have been since 2021: with an unchecked illicit market.” Personal possession and home cultivation have been legal in Virginia since 2021, but no licensed retail framework has been established. This is the second gubernatorial veto of a cannabis sales bill in the state’s recent legislative history.
University of Pennsylvania Study Links Medical Cannabis to 65 Per Cent Reduction in Opioid Use
A prospective observational study from the University of Pennsylvania, published in the journal Cureus, found that medical cannabis reduced mean daily opioid consumption by 65 per cent among chronic pain patients over a five-month follow-up. The 29 participants, drawn from a university outpatient pain clinic, cut opioid use from 46.8 morphine milligram equivalents per day at baseline to 16.2 MMEs per day within the first month, with seven patients stopping opioid therapy entirely. Pain scores and physical functioning both improved throughout the study period. Researchers describe it as the first prospective study to evaluate medical cannabis as an opioid alternative in a setting where patient cost was not a barrier. The paper carries acknowledged caveats around the small sample and single-site design. The Marijuana Herald reported the findings.
Schedule III Is “Most Consequential Federal Change in 50 Years” but Is Not Legalisation, Say Saul Ewing Partners
Speaking ahead of Cannabis Europa London (26–27 May), Jonathan Havens and Adam Fayne, partners at law firm Saul Ewing, argue that the DEA’s April rescheduling is historic but frequently misread. In an interview with Business of Cannabis, Havens describes the move as “the most consequential federal change to cannabis law in more than 50 years,” pointing to the elimination of the Section 280E tax disallowance — which had pushed effective federal rates above 70 per cent for some operators — and the creation of new DEA registration and import-export permitting pathways. The pair stress, however, that Schedule III “is not federal legalisation”: adult-use operations remain unaddressed pending the 29 June administrative hearing, banking reform is unresolved, and the legal architecture spanning import-export permits, divergent hemp definitions, and FDA-EMA alignment requires specialist expertise to navigate. GMP-compliant European producers are identified as among the clearest near-term beneficiaries of the new cross-border permitting framework.
Cielo Verde Founder Warns Against Commoditisation as European Cannabis Market Matures
Barry Laxer, founder and president of Canadian cannabis producer Cielo Verde, says the European medical cannabis market is shifting “from early supply-driven dynamics toward a more sophisticated ecosystem where quality, reliability, and long-term partnerships matter.” Speaking to Business of Cannabis for its Voices of Cannabis Europa series, Laxer cautions operators against competing on volume, arguing that sustainable businesses must create “value beyond price alone” through strong brand positioning, distinct terpene profiles, and consistent product performance. He identifies the premium segment as underserved and points to research collaborations with McGill’s cannabis research centre and Quebec’s quality control chemists as differentiators for Cielo Verde’s European positioning. The company sponsors the Clinic of the Year award at Cannabis Europa, reflecting its focus on patient-centred care and physician education. See further analysis on the EU Cannabis Regulation hub.
Watch this week for any signal on whether Virginia’s General Assembly will attempt a veto override, and for developments from the Cannabis Europa London conference beginning 26 May. The DEA’s administrative hearing on broader cannabis rescheduling is set for 29 June; 20 May marks the postal deadline for written notices of intent to participate.
The post Cannabis News Today — Wednesday 20 May 2026: Virginia Governor Kills Sales Bill as DOT Holds Line on Transport Drug Testing appeared first on Business of Cannabis.
Continue reading...
